Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor-Reference-Cited by-同舟云学术

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor

Published:2014-04-09 Issue:14 Volume:311 Page:1430
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Lee June-Koo¹,Hahn Seokyung²,Kim Dong-Wan³,Suh Koung Jin¹,Keam Bhumsuk³,Kim Tae Min³,Lee Se-Hoon³,Heo Dae Seog³

Affiliation:

1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

2. Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea3Department of Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

3. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea4Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of targeting the mTOR pathway to regulate ferroptosis in NSCLC with different EGFR mutations;Oncology Letters;2024-05-01

2. Lung Cancer;Side Effects of Cancer Therapy;2024

3. Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis;Frontiers in Immunology;2023-07-13

4. Antitumor effects of erlotinib in combination with berberine in A431 cells;BMC Pharmacology and Toxicology;2023-05-11

5. Nanomedicines: intervention in inflammatory pathways of cancer;Inflammopharmacology;2023-04-15